Report results from the ongoing Phase 3 Dupixent trial in biologic-naïve patients with chronic spontaneous urticaria
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 2 Nov 2023
- Due
- 31 Dec 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“An ongoing Phase 3 clinical trial (in biologic-naïve patients) continues to enroll patients, with results expected in late 2024.”
What we found
Evidence strength A What the grades mean
A later 10-K states results from the biologic-naïve CSU Phase 3 trial were reported in September 2024, before the year-end 2024 deadline.
-
A Regeneron Pharmaceuticals 10-K filed 2025-02-05
“we reported results from a confirmatory Phase 3 clinical trial of Dupixent in CSU (in biologic-naïve patients) in September 2024” ✓ confirmed on the page
-
A Regeneron Pharmaceuticals 10-K filed 2025-02-05
“Reported that second Phase 3 trial in CSU in biologic-naïve patients met its primary and key secondary endpoints” ✓ confirmed on the page
Market reaction: the shares moved +2.0% against the S&P 500 over the three sessions around the disclosure (4 Feb 2025 to 7 Feb 2025). What this measures
Checked 10 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout late
- Indicative materiality
- High rules
- Action
- Report
- Deliverable
- Phase 3 Dupixent CSU trial results in biologic-naïve patients
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Regeneron Pharmaceuticals? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-REGN-006347 · Corrections policy